Candel Therapeutics jumps on orphan drug tag for lead cancer therapy

Candel Therapeutics

11/04/2024 14:26

** Shares of Candel Therapeutics  CADL.O  climb 23.5% to
$6.3 premarket 
    ** Says U.S. FDA has granted "orphan drug" designation for
its lead investigational therapy, CAN-2409, for the treatment of
a type of pancreatic cancer
    ** Status given to drugs that treat rare conditions and are
protected through a series of government incentives once in
market 
    ** Already has "fast track" status that expedites the review
of drug candidates being developed to treat serious conditions
    ** Up to last close, stock up 246.9% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))